CARDIAC INVOLVEMENT IN RARE HEMATOLOGICAL DISEASES
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Cardiac involvement in hematological disorders represents a major determinant of morbidity and mortality, arising both from the intrinsic pathophysiology of the diseases and from treatment-related toxicity. While cardiotoxicity in malignant hematologic conditions has been clearly recognized, cardiac manifestations in rare non-malignant hematologic disorders remain under-explored. This chapter provides a comprehensive review of the mechanisms, clinical presentations, and management of cardiac involvement in paroxysmal nocturnal hemoglobinuria (PNH), megaloblastic changes, infantile myelofibrosis, sitosterolemia, hypereosinophilic syndrome (HES), aplastic anemia, and cytokine release syndrome (CRS).In PNH, complement mediated intravascular hemolysis leads to nitric oxide depletion, endothelial dysfunction, and microvascular thrombosis, predisposing to pulmonary hypertension, myocardial ischemia, and right-sided heart failure. Megaloblastic anemia imposes a chronic high-output state secondary to severe anemia and ineffective erythropoiesis, ultimately causing ventricular hypertrophy and failure. In infantile myelofibrosis, marrow fibrosis shifts hematopoiesis to extramedullary sites, resulting in hepatosplenomegaly, increased venous outflow, and high output circulation that progressively overloads the myocardium. Sitosterolemia, a lipid-metabolism disorder due to ABCG5/ABCG8 mutations, causes arterial plant sterol deposition, foam-cell formation, valvular calcification, and myocardial fibrosis, producing early-onset atherosclerosis and premature cardiac death. Cardiac injury also occurs in HES, where eosinophil degranulation induces a three-stage sequence of necrosis, thrombosis, and endomyocardial fibrosis leading to restrictive cardiomyopathy. In aplastic anemia and other bone-marrow failure syndromes, chronic anemia and transfusion-related iron overload cause myocardial hypertrophy and dilated cardiomyopathy. Moreover, CRS following advanced immunotherapies (CAR-T cells, bispecific antibodies) can provoke acute, reversible myocardial dysfunction through cytokine-mediated inflammation and vascular leak.As conclusion, the mechanisms of cardiac damage converge on hemodynamic overload, microvascular thrombosis, metabolic stress, and inflammation. Early recognition through echocardiography, cardiac biomarkers, and clinical awareness is crucial. Preventive and therapeutic measures such as iron chelation, cardioprotective agents, immunomodulation, and targeted disease-specific therapy significantly improve outcomes. Multidisciplinary management involving hematology, cardiology, and genetics is essential to optimize survival and quality of life. By delineating shared and disease-specific pathways of cardiac involvement, this chapter underscores the need for integrated cardio-hematological care in rare hematologic disorders.Keywords: Cardiac involvement; Rare hematological disorders; Paroxysmal nocturnal hemoglobinuria; Myelofibrosis; Sitosterolemia
Fields of Study & Subjects
Eosinophilic Disorders and Syndromes
Chemotherapy-induced cardiotoxicity and mitigation
Cardiomyopathy and Myosin Studies
Publication details
- Journal / source
- Turkiye Klinikleri eBooks
- Pages
- 301–308
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Book chapter